Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
DGNeurologie
Erschienen in: DGNeurologie 1/2020

19.12.2019 | Neuropathischer Schmerz | Leitlinie

S2k-Leitlinie: Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen

Zusammenfassung der Leitlinie der Deutschen Gesellschaft für Neurologie

verfasst von: PD Dr. Tanja Schlereth

Erschienen in: DGNeurologie | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Auszug

  • Im Jahr 2015 wurden von der NeuPSIG (Neuropathic Pain Special Interest Group der IASP) aktuelle Therapieempfehlungen zur Therapie neuropathischer Schmerzen erstellt nach einer systematischen Literaturrecherche und einer Metaanalyse, die in dieser Leitlinie berücksichtigt werden.
  • Im Jahr 2017 trat ein neues Gesetz in Kraft („Cannabisgesetz“), mit dem Cannabinoide (Cannabisblüten, Cannabisextrakte, Dronabinol, Nabilon, Nabiximols) auf Antrag bei den Krankenkassen erstattungsfähig wurden und mittels Betäubungsmittel (BTM)-Rezept verordnet werden können. Es handelt sich weiterhin um einen „off-label use“, da keine dieser Substanzen in der Indikation „Schmerz“ zugelassen ist.
  • Die IASP (= International Association for the Study of Pain) hat neben neuropathischen und nozizeptiven Schmerzen noch die Entität „noziplastischer Schmerzen“ definiert (siehe unten).
  • Als mögliche Ursache einer idiopathischen Small-Fiber-Neuropathie konnten Mutationen der spannungsgeladenen Natriumkanäle (Nav1.7, Nav1.8 und Nav1.9) sowie TRPA1 gefunden werden.
  • Die korneale konfokale Mikroskopie ist ein nichtinvasives diagnostisches Verfahren zur Diagnostik von Small-Fiber-Neuropathien.
…
Literatur
1.
Treede RD et al (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70(18):1630–1635PubMed
2.
van Hecke O et al (2014) Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 155(4):654–662PubMed
3.
Baron R, Binder A, Wasner G (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9(8):807–819PubMed
4.
5.
van Hecke O et al (2015) Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations. Pain 156(11):2337–2353PubMedPubMedCentral
6.
Finnerup NB et al (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain 157(8):1599–1606PubMedPubMedCentral
7.
Maier C et al (2010) Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 150(3):439–450PubMed
8.
Westermann A et al (2011) Pain-associated mild sensory deficits without hyperalgesia in chronic non-neuropathic pain. Clin J Pain 27(9):782–789PubMed
9.
Backonja MM et al (2013) Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain 154(9):1807–1819PubMed
10.
Cruccu G et al (2010) EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 17(8):1010–1018PubMed
11.
Haanpaa M et al (2011) NeuPSIG guidelines on neuropathic pain assessment. Pain 152(1):14–27PubMed
12.
Lauria G et al (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 17(7):903–909PubMed
13.
Garcia-Larrea L et al (2002) Laser-evoked potential abnormalities in central pain patients: the influence of spontaneous and provoked pain. Brain 125(Pt 12):2766–2781PubMed
14.
Valeriani M et al (2012) Clinical usefulness of laser evoked potentials. Neurophysiol Clin 42(5):345–353PubMed
15.
Omori S et al (2017) Pain-related evoked potentials after intraepidermal electrical stimulation to Adelta and C fibers in patients with neuropathic pain. Neurosci Res 121:43–48PubMed
16.
Hansen N et al (2015) Amplitudes of pain-related evoked potentials are useful to detect small fiber involvement in painful mixed fiber neuropathies in addition to quantitative sensory testing—an Electrophysiological study. Front Neurol 6:244PubMedPubMedCentral
17.
Cruzat A, Qazi Y, Hamrah P (2017) In vivo confocal microscopy of corneal nerves in health and disease. Ocul Surf 15(1):15–47PubMed
18.
Ziegler D et al (2014) Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes 63(7):2454–2463PubMed
19.
Chen X et al (2015) Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Care 38(6):1138–1144PubMedPubMedCentral
20.
Weidner C et al (2000) Acute effects of substance P and calcitonin gene-related peptide in human skin—a microdialysis study. J Invest Dermatol 115(6):1015–1020PubMed
21.
22.
Kramer HH et al (2004) Electrically stimulated axon reflexes are diminished in diabetic small fiber neuropathies. Diabetes 53(3):769–774PubMed
23.
Bickel A et al (2009) C‑fiber axon reflex flare size correlates with epidermal nerve fiber density in human skin biopsies. J Peripher Nerv Syst 14(4):294–299PubMed
24.
Kalliomaki M et al (2011) Structural and functional differences between neuropathy with and without pain? Exp Neurol 231(2):199–206PubMed
25.
Schley M et al (2012) Skin innervation at different depths correlates with small fibre function but not with pain in neuropathic pain patients. Eur J Pain 16(10):1414–1425PubMed
26.
Bickel A et al (2002) Assessment of the neurogenic flare reaction in small-fiber neuropathies. Neurology 59(6):917–919PubMed
27.
Green AQ, Krishnan ST, Rayman G (2009) C‑fiber function assessed by the laser doppler imager flare technique and acetylcholine iontophoresis. Muscle Nerve 40(6):985–991PubMed
28.
Koppert W et al (2004) Mechanically induced axon reflex and hyperalgesia in human UV‑B burn are reduced by systemic lidocaine. Eur J Pain 8(3):237–244PubMed
29.
Krishnan ST, Rayman The LDIflare G (2004) The LDIflare: a novel test of C‑fiber function demonstrates early neuropathy in type 2 diabetes. Diabetes Care 27(12):2930–2935PubMed
30.
Kubasch ML et al (2017) Laser doppler assessment of vasomotor axon reflex responsiveness to evaluate neurovascular function. Front Neurol 8:370PubMedPubMedCentral
31.
32.
Freynhagen R et al (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22(10):1911–1920PubMed
33.
Bouhassira D et al (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114(1–2):29–36PubMed
34.
Bennett M (2001) The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 92(1–2):147–157PubMed
35.
Bouhassira D et al (2004) Development and validation of the Neuropathic Pain Symptom Inventory. Pain 108(3):248–257PubMed
36.
Galer BS, Jensen MP (1997) Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 48(2):332–338PubMed
37.
38.
39.
Finnerup NB et al (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14(2):162–173PubMedPubMedCentral
40.
Waldfogel JM et al (2017) Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review. Neurology 88(20):1958–1967PubMed
41.
42.
Griebeler ML et al (2014) Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med 161(9):639–649PubMed
43.
Thomas AM, Atkinson TJ (2018) Old friends with new faces: are sodium channel blockers the future of adjunct pain medication management? J Pain 19(1):1–9PubMed
44.
45.
Snedecor SJ et al (2014) Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 14(2):167–184PubMed
46.
Demant DT et al (2014) The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 155(11):2263–2273PubMed
47.
Sindrup SH et al (2017) Impact of etiology and duration of pain on pharmacological treatment effects in painful polyneuropathy. Eur J Pain 21(8):1443–1450PubMed
48.
Min K et al (2016) Symptom-based treatment of neuropathic pain in spinal Cord-injured patients: a randomized crossover clinical trial. Am J Phys Med Rehabil 95(5):330–338PubMed
49.
Holbech JV et al (2016) Pain phenotype as a predictor for drug response in painful polyneuropathy‑a retrospective analysis of data from controlled clinical trials. Pain 157(6):1305–1313PubMed
50.
Thienel U et al (2004) Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 110(4):221–231PubMed
51.
52.
53.
54.
55.
56.
Saudek CD, Werns S, Reidenberg MM (1977) Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 22(2):196–199PubMed
57.
Chadda VS, Mathur MS (1978) Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 26(5):403–406PubMed
58.
59.
60.
61.
Goldstein DJ et al (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116(1–2):109–118PubMed
62.
Raskin J et al (2005) A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6(5):346–356PubMed
63.
Wernicke JF et al (2006) A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67(8):1411–1420PubMed
64.
Sultan A et al (2008) Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 8:29PubMedPubMedCentral
65.
Ney JP et al (2013) Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. Pain Med 14(5):706–719PubMed
66.
Kajdasz DK et al (2007) Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 29(Suppl):2536–2546PubMed
67.
Boyle J et al (2012) Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 35(12):2451–2458PubMedPubMedCentral
68.
69.
Lindner V, Deuschl G (2004) Antidepressants and anticonvulsive agents. Practical utility profile in pain therapy. Schmerz 18(1):53–60PubMed
70.
71.
72.
Durand JP et al (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23(1):200–205PubMed
73.
Rowbotham MC et al (2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110(3):697–706PubMed
74.
Sindrup SH et al (2003) Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60(8):1284–1289PubMed
75.
Attal N et al (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17(9):1113–e88PubMed
76.
Otto M et al (2008) Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain 139(2):275–283PubMed
77.
Shimodozono M et al (2002) Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. Int J Neurosci 112(10):1173–1181PubMed
78.
Sindrup SH et al (1992) The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 52(5):547–552PubMed
79.
Sindrup SH et al (1990) The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42(2):135–144PubMed
80.
Nishihara M et al (2013) Combinations of low-dose antidepressants and low-dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases. Pain Physician 16(5):E547–E552PubMed
81.
Moulin D et al (2014) Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 19(6):328–335PubMedPubMedCentral
82.
Sommer C et al (2015) Opioids in chronic neuropathic pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Schmerz 29(1):35–46PubMed
83.
84.
Vinik AI et al (2014) A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care 37(8):2302–2309PubMed
85.
Schwartz S et al (2015) A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig 35(2):95–108PubMed
86.
87.
88.
89.
90.
91.
92.
Meng H et al (2017) Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg 125(5):1638–1652PubMed
93.
Aviram J, Samuelly-Leichtag G (2017) Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician 20(6):E755–E796PubMed
94.
Petzke F, Enax-Krumova EK, Hauser W (2016) Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: a systematic review of randomized controlled studies. Schmerz 30(1):62–88PubMed
95.
Iskedjian M et al (2007) Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 23(1):17–24PubMed
96.
Hauser W, Petzke F, Fitzcharles MA (2018) Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management—An overview of systematic reviews. Eur J Pain 22(3):455–470PubMed
97.
98.
99.
Cakici N et al (2016) Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med 33(11):1466–1476PubMed
100.
101.
  Ziegler D et al (2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 21(2):114–121PubMed
102.
  Dy SM et al (2017) AHRQ comparative effectiveness reviews. In: Preventing complications and treating symptoms of diabetic peripheral neuropathy. Agency for Healthcare Research and Quality, Rockville
103.
  Ziegler D et al (2011) Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 34(9):2054–2060PubMedPubMedCentral
104.
  Aiyer R et al (2018) A systematic review of NMDA receptor antagonists for treatment of Neuropathic pain in clinical practice. Clin J Pain 34(5):450–467PubMed
105.
  Cvrcek P (2008) Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med 9(2):253–257PubMed
106.
  Eide PK, Stubhaug A, Stenehjem AE (1995) Central dysesthesia pain after traumatic spinal cord injury is dependent on N‑methyl-D-aspartate receptor activation. Neurosurgery 37(6):1080–1087PubMed
107.
  Vo T, Rice AS, Dworkin RH (2009) Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain 143(3):169–171PubMed
108.
109.
110.
111.
  Baron R et al (2009) 5 % lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 25(7):1663–1676PubMed
112.
113.
  Navez ML et al (2015) 5 % Lidocaine Medicated Plaster for the Treatment of Postherpetic Neuralgia: A Review of the Clinical Safety and Tolerability. Pain Ther 4(1):1–15PubMedPubMedCentral
114.
115.
  Mou J et al (2013) Efficacy of Qutenza (R) (capsaicin) 8 % patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database. Pain 154(9):1632–1639PubMed
116.
  van Nooten F et al (2017) Capsaicin 8 % patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther 39(4):787–803PubMed
117.
118.
  Lakhan SE, Velasco DN, Tepper D (2015) Botulinum toxin‑A for painful diabetic neuropathy: a meta-analysis. Pain Med 16(9):1773–1780PubMed
119.
  Shackleton T et al (2016) The efficacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses. Oral Surg Oral Med Oral Pathol Oral Radiol 122(1):61–71PubMed
120.
  Attal N et al (2016) Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 15(6):555–565PubMed
121.
  Thompson DF, Brooks KG (2015) Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther 40(5):496–503PubMed
122.
  Ho KY et al (2008) Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain 24(1):51–55PubMed
123.
124.
125.
  Heutink M et al (2012) The CONECSI trial: results of a randomized controlled trial of a multidisciplinary cognitive behavioral program for coping with chronic neuropathic pain after spinal cord injury. Pain 153(1):120–128PubMed
126.
  Miziara ID et al (2009) Group psychotherapy: an additional approach to burning mouth syndrome. J Psychosom Res 67(5):443–448PubMed
127.
  Arnold B et al (2014) Multimodal pain therapy for treatment of chronic pain syndrome. Consensus paper of the ad hoc commission on multimodal interdisciplinary pain management of the German Pain Society on treatment contents. Schmerz 28(5):459–472PubMed
128.
  Heutink M et al (2014) Long-term outcomes of a multidisciplinary cognitive behavioural programme for coping with chronic neuropathic spinal cord injury pain. J Rehabil Med 46(6):540–545PubMed
129.
  Burns AS et al (2013) Evaluation of an interdisciplinary program for chronic pain after spinal cord injury. PM R 5(10):832–838PubMed
Metadaten
Titel
S2k-Leitlinie: Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen
Zusammenfassung der Leitlinie der Deutschen Gesellschaft für Neurologie
verfasst von
PD Dr. Tanja Schlereth
Publikationsdatum
19.12.2019
Verlag
Springer Medizin
Erschienen in
DGNeurologie / Ausgabe 1/2020
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI
https://doi.org/10.1007/s42451-019-00139-8

Weitere Artikel der Ausgabe 1/2020

DGNeurologie 1/2020 Zur Ausgabe

Neuro-Quiz

Therapierefraktärer Gesichtsschmerz mit progredienten Hirnnervenausfällen

Der interessante Fall

Die Sinne schwinden – Welche seltene Erkrankung steckt dahinter?

Im Fokus

Reha nach Schlaganfall: „Entspannung besser als Laufbandtraining?“

Arzneimitteltherapie

Therapie der Altersepilepsie

Magazin

Magazin

Eine Frage des Rechts

Wem gehören die medizinisch wissenschaftlichen Leitlinien?

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

19.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Hustenstiller lindert Agitation bei Alzheimer
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise